Eduardo Lacson1,2, Christos P Argyropoulos3, Harold J Manley2, Gideon Aweh2, Andrew I Chin4, Loay H Salman5, Caroline M Hsu6, Doug S Johnson2, Daniel E Weiner6. 1. Division of Nephrology, Tufts Medical Center, Boston, Massachusetts elacson@tuftsmedicalcenter. 2. Dialysis Clinic, Inc., Nashville, Tennessee. 3. Division of Nephrology, University of New Mexico School of Medicine, Albuquerque, New Mexico. 4. Division of Nephrology, University of California, Sacramento, California. 5. Division of Nephrology, Albany Medical College, Albany, New York. 6. Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.
Abstract
BACKGROUND: Patients receiving maintenance dialysis represent a high-risk, immune-compromised population with 15%-25% COVID-19 mortality rate who were unrepresented in clinical trials of mRNA vaccines. METHODS: All patients receiving maintenance dialysis who received two doses of SARS-CoV-2 mRNA vaccines with antibody test results drawn ≥14 days after the second dose, as documented in the electronic health record through March 18, 2021, were included. Response was on the basis of levels of Ig-G against the receptor binding domain of the S1 subunit of SARS-CoV-2 spike-antigen (seropositive ≥2 U/L) using an FDA-approved semiquantitative chemiluminescent assay (ADVIA Centaur XP/XPT COV2G). RESULTS: Among 186 patients on dialysis from 30 clinics in eight states tested 23±8 days after receiving two vaccine doses, there were 165 (88.7%) responders with 70% at maximum titer. There was no significant difference between BNT162b2/Pfizer (148 out of 168, 88.1%) and mRNA-1273/Moderna (17 out of 18, 94.4%), P=0.42. All 38 patients with COVID-19 history were responders, with 97% at maximum titer. Among patients without COVID-19, 127 out of 148 (85.8%) were responders, comparable between BNT162b2/Pfizer (113 out of 133) and mRNA-1273/Moderna (14 out of 15) vaccines (85.0% versus 93.3%, P=0.38). CONCLUSIONS: Most patients receiving maintenance dialysis responded after two doses of BNT162b2/Pfizer or mRNA-1273/Moderna vaccine, suggesting the short-term development of antispike antibody is good, giving hope that most of these patients who are vulnerable, once immunized, will be protected from COVID-19. Longer-term evaluation is needed to determine antibody titer durability and if booster dose(s) are warranted. Further research to evaluate the approach to patients without a serologic response is needed, including benefits of additional dose(s) or administration of alternate options.
BACKGROUND: Patients receiving maintenance dialysis represent a high-risk, immune-compromised population with 15%-25% COVID-19 mortality rate who were unrepresented in clinical trials of mRNA vaccines. METHODS: All patients receiving maintenance dialysis who received two doses of SARS-CoV-2 mRNA vaccines with antibody test results drawn ≥14 days after the second dose, as documented in the electronic health record through March 18, 2021, were included. Response was on the basis of levels of Ig-G against the receptor binding domain of the S1 subunit of SARS-CoV-2 spike-antigen (seropositive ≥2 U/L) using an FDA-approved semiquantitative chemiluminescent assay (ADVIA Centaur XP/XPT COV2G). RESULTS: Among 186 patients on dialysis from 30 clinics in eight states tested 23±8 days after receiving two vaccine doses, there were 165 (88.7%) responders with 70% at maximum titer. There was no significant difference between BNT162b2/Pfizer (148 out of 168, 88.1%) and mRNA-1273/Moderna (17 out of 18, 94.4%), P=0.42. All 38 patients with COVID-19 history were responders, with 97% at maximum titer. Among patients without COVID-19, 127 out of 148 (85.8%) were responders, comparable between BNT162b2/Pfizer (113 out of 133) and mRNA-1273/Moderna (14 out of 15) vaccines (85.0% versus 93.3%, P=0.38). CONCLUSIONS: Most patients receiving maintenance dialysis responded after two doses of BNT162b2/Pfizer or mRNA-1273/Moderna vaccine, suggesting the short-term development of antispike antibody is good, giving hope that most of these patients who are vulnerable, once immunized, will be protected from COVID-19. Longer-term evaluation is needed to determine antibody titer durability and if booster dose(s) are warranted. Further research to evaluate the approach to patients without a serologic response is needed, including benefits of additional dose(s) or administration of alternate options.
Authors: J Bergström; B Lindholm; E Lacson; W Owen; E G Lowrie; R J Glassock; T A Ikizler; F J Wessels; L L Moldawer; C Wanner; J Zimmermann Journal: Semin Dial Date: 2000 May-Jun Impact factor: 3.455
Authors: Marta Crespo; Silvia Collado; Marisa Mir; Higini Cao; Francesc Barbosa; Consol Serra; Carlota Hidalgo; Anna Faura; Milagros Montero; Juan García de Lomas; Juan P Horcajada; Josep M Puig; Julio Pascual Journal: Clin J Am Soc Nephrol Date: 2011-08-18 Impact factor: 8.237
Authors: Caroline M Hsu; Daniel E Weiner; Gideon Aweh; Dana C Miskulin; Harold J Manley; Carol Stewart; Vlad Ladik; John Hosford; Edward C Lacson; Douglas S Johnson; Eduardo Lacson Journal: Am J Kidney Dis Date: 2021-01-17 Impact factor: 8.860
Authors: Caroline M Hsu; Daniel E Weiner; Harold J Manley; Gideon N Aweh; Vladimir Ladik; Jill Frament; Dana Miskulin; Christos Argyropoulos; Kenneth Abreo; Andrew Chin; Reginald Gladish; Loay Salman; Doug Johnson; Eduardo K Lacson Journal: Clin J Am Soc Nephrol Date: 2022-02-10 Impact factor: 8.237
Authors: Damien R Ashby; Ben Caplin; Richard W Corbett; Elham Asgari; Nicola Kumar; Alexander Sarnowski; Richard Hull; David Makanjuola; Nicholas Cole; Jian Chen; Sofia Nyberg; Kieran McCafferty; Faryal Zaman; Hugh Cairns; Claire Sharpe; Kate Bramham; Reza Motallebzadeh; Kashif Jamil Anwari; Alan D Salama; Debasish Banerjee Journal: Clin J Am Soc Nephrol Date: 2022-06 Impact factor: 10.614
Authors: Shuchi Anand; Maria E Montez-Rath; Jialin Han; Pablo Garcia; LinaCel Cadden; Patti Hunsader; Russell Kerschmann; Paul Beyer; Mary Dittrich; Geoffrey A Block; Scott D Boyd; Julie Parsonnet; Glenn M Chertow Journal: medRxiv Date: 2021-05-12
Authors: André Weigert; Marie-Louise Bergman; Lígia A Gonçalves; Iolanda Godinho; Nádia Duarte; Rita Abrantes; Patrícia Borges; Ana Brennand; Vanessa Malheiro; Paula Matoso; Onome Akpogheneta; Lindsay Kosack; Pedro Cruz; Estela Nogueira; Magda Pereira; Ana Ferreira; Marco Marques; Telmo Nunes; João Faro-Viana; Jocelyne Demengeot; Carlos Penha-Gonçalves Journal: Front Med (Lausanne) Date: 2021-12-24
Authors: Georg Beilhack; Rossella Monteforte; Florian Frommlet; Martina Gaggl; Robert Strassl; Andreas Vychytil Journal: Front Immunol Date: 2021-12-02 Impact factor: 7.561
Authors: Edward J Carr; Andreas Kronbichler; Matthew Graham-Brown; Graham Abra; Christos Argyropoulos; Lorraine Harper; Edgar V Lerma; Rita S Suri; Joel Topf; Michelle Willicombe; Swapnil Hiremath Journal: Kidney Int Rep Date: 2021-07-06